|
| Receptors | Peptide | Cancer | Labeling |
|
| Somatostatin receptor | Somatostatin | Neuroendocrine tumors |
68Ga-DOTA, 68Ga-NOTA, 64Cu-TETA, 64Cu-DOTA, 64Cu-NOTA, 64Cu-CB-TE2A, 18F-NFP, 18F-SFB, and so forth |
| Gastrin-releasing peptide receptor (GRPR) | Bombesin | Prostate cancer, breast cancer, Gastrointestinal stromal tumor |
| -integrin | RGD | Brain cancer, lung cancer, breast cancer, and so forth |
|
| Melanocortin 1 receptor (MC1R) | -MSH | Melanomas |
18F-SFB, 68Ga-DOTA, 64Cu-TETA, 64Cu-DOTA, 64Cu-CB-TE2A |
|
| Cholecystokinin B/gastrin receptor (CCK2/CCK-B) | CCK/gastrin | Medullary thyroid cancer |
18F-SFB, 68Ga-DOTA, 64Cu-DOTA |
|
| Glucagon-like peptide-1 receptor (GLP-1) | Exendin | Insulinoma cancer |
18F-FBEM, 68Ga-DOTA |
|
| Neurotensin receptor (NTR1) | Neurotensin | Small cell lung cancer, colon cancer, and so forth |
68Ga-DOTA
18F-FB |
|
| Neuropeptide Y receptor (Y1) | NPY | Breast cancer, prostate cancer |
64Cu-DOTA |
|
| Luteinizing hormone-releasing hormone receptor (LHRH-R) | LHRH | Prostate cancer, breast cancer, and so forth |
68Ga-DOTA |
|
| Neurokinin 1 receptor (NK-1) | Substance P | Glioblastoma | |
|
| Vasoactive intestinal peptide receptor (VIP-R) | Vasoactive intestinal peptide (VIP) | Prostate cancer |
64Cu-DOTA
18F-FB |
|
| Pituitary adenylate cyclase-activating peptide (PACAP) receptor | Pituitary adenylate cyclase-activating peptide (PACAP) | Breast cancer |
64Cu-DOTA |
|
| Chemokine receptor 4 (CXCR4) | CXCR4 | Lymphatic system, lung cancer, and so forth |
18F-SFB, 68Ga-DOTA, 64Cu-DOTA |
|
